Obstructive ureteral disease requiring temporary urinary drainage with a double-J ureteral stent Associated double-J stent–related lower urinary tract symptoms (dysuria, frequency, urgency, flank pain) and stent-related discomfort lithiasis, double J stent
Conditions
Interventions
Group B (Experimental Group):
Levocetirizine (XYZAL) 5 mg oral tablet once daily
Administration starts at least 2 hours pre-operatively and continues daily until stent removal (maximum 3 weeks)
Giv
placement of double J + giving either xyal 5mg daily or olacebo than double j removal and evaluationg irritating symptoms
double J stent, lithiasis, antihistamin
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Adults aged 18 years or older. Patients who underwent double J ureteral stent placement for obstructive ureteral disease at CHU-NDS. Patients who are able and willing to provide written informed consent. Patients capable of complying with study procedures and follow-up requirements.
Exclusion criteria
Exclusion criteria: Exclusion criteria: Radiation-induced ureteritis Pregnancy or breastfeading Malignancy or extrinsic ureter obstruction Known allergy or CI to the study drugs Previous ureteral stenting Patient taking anti-allergic in the previous month Refusal to provide consent
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Name: VAS;Timepoints: upon ureteroscopy;Measure: visual analogue pain scale | — |
Primary
| Measure | Time frame |
|---|---|
| Name: Ureteral inflammation ;Timepoints: uponureteroscopy;Measure: macroscopically (inflammed or no);Name: double J stent;Timepoints: upon ureteroscopy;Measure: calcified or no;Name: USSQ;Timepoints: after ureteroscopy;Measure: ureteral stent symptoms questionnaire | — |
Countries
Lebanon
Contacts
Public Contactrodrigue saad
supervisor
Outcome results
None listed